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Abstract
Background: Inhalation anthrax is characterized by a systemic spread of the challenge agent, Bacillus
anthracis. It causes severe damage, including multiple hemorrhagic lesions, to host tissues and organs. It is
widely believed that anthrax lethal toxin secreted by proliferating bacteria is a major cause of death,
however, the pathology of intoxication in experimental animals is drastically different from that found
during the infectious process. In order to close a gap between our understanding of anthrax molecular
pathology and the most prominent clinical features of the infectious process we undertook bioinformatic
and experimental analyses of potential proteolytic virulence factors of B. anthracis distinct from lethal toxin.
Methods: Secreted proteins (other than lethal and edema toxins) produced by B. anthracis were tested
for tissue-damaging activity and toxicity in mice. Chemical protease inhibitors and rabbit immune sera
raised against B. anthracis proteases were used to treat mice challenged with B. anthracis (Sterne) spores.
Results: B. anthracis strain delta Ames (pXO1-, pXO2-) producing no lethal and edema toxins secrets a
number of metalloprotease virulence factors upon cultivation under aerobic conditions, including those
with hemorrhagic, caseinolytic and collagenolytic activities, belonging to M4 and M9 thermolysin and
bacterial collagenase families, respectively.
These factors are directly toxic to DBA/2 mice upon intratracheal administration at 0.5 mg/kg and higher
doses. Chemical protease inhibitors (phosphoramidon and 1, 10-phenanthroline), as well as immune sera
against M4 and M9 proteases of B. anthracis, were used to treat mice challenged with B. anthracis (Sterne)
spores. These substances demonstrate a substantial protective efficacy in combination with ciprofloxacin
therapy initiated as late as 48 h post spore challenge, compared to the antibiotic alone.
Conclusion: Secreted proteolytic enzymes are important pathogenic factors of B. anthrasis, which can be
considered as effective therapeutic targets in the development of anthrax treatment and prophylactic
approaches complementing anti-lethal toxin therapy.
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Background
Inhalation anthrax is a severe, often fatal disease charac-
terized by systemic spread of the challenge agent, Bacillus
anthracis, which is capable of causing severe damage to
host tissues and organs. Multiple hemorrhagic lesions in
the mediastinum, mediastinal lymph nodes, bronchi,
lungs, heart, spleen, liver, intestines, kidneys, adrenal
glands, and/or central nervous system are typically found
upon postmortem examination of patients who suc-
cumbed to inhalation anthrax. The most dramatic and
potentially life-threatening changes were observed in the
vascular system with a diffuse vasculitis extending from
moderate sized arteries and veins down to the capillary
level. The vasculitis was often associated with vessel
destruction, especially of the smallest vessels, and was typ-
ically accompanied by massive necrosis in some tissues
[1-3]. It is widely believed that anthrax lethal toxin (LT)
secreted by proliferating bacteria is a major cause of death
in man and in several other susceptible animal species [4].
However, the pathology of intoxication in experimental
animals is drastically different from that found during the
natural infectious process. Recent extensive analyses in
mice and rats challenged with a highly purified lethal
toxin [5,6] confirmed earlier observations [7] that toxin
activity caused no gross pathology and almost solely man-
ifested in hypoxic liver failure. In addition to lethal toxin,
the hemorrhagic and other tissue-damaging factors elabo-
rated by B. anthracis could play important virulence-
enhancing roles but these factors have not yet been char-
acterized. Early publications using culture filtrates of B.
anthracis  assumed that the observed effects of secreted
substances were caused entirely by LT [8,9]. It is also pos-
sible that these other factors could themselves exhibit a
direct lethal effect.
The capacity of bacteria to cause destruction of tissues, as
well as other pathological consequences such as degrada-
tion of immunoglobulins, cytokines and complement,
release of inflammatory mediators, or activation of host
proteolytic enzymes, is attributed to a wide variety of
secreted proteases [10], however in the case of B. anthracis
the proteases of this microorganism, other than lethal fac-
tor, have attracted little attention in the scientific litera-
ture. The current study aimed to carry out an initial
characterization of certain B. anthracis proteolytic
enzymes and to obtain evidence on their possible patho-
genic role in anthrax.
Methods
Microbial strains
The non-encapsulated Bacillus anthracis strain 34F2
(Sterne) [pXO1+, pXO2-] obtained from the Colorado
Serum Company (Boulder, CO) was used in animal chal-
lenge experiments. The 50% lethal doses (LD50s) by the
intraperitoneal (i.p.) route were established earlier
(Popov et al., 2004) and the LD50 value for intraperitoneal
challenge for DBA/2 mice was found to be 3 × 106 spores
per mouse. The non-encapsulated, atoxigenic strain of B.
anthracis (delta Ames) [pXO1-, pXO2-] was kindly pro-
vided by Dr. J. Shiloach (National Institutes of Health,
Bethesda, MD). B. cereus strain ATCC #11778 and B. sub-
tilis strain #23857 were purchased from American Type
Culture Collection (Manassas, VA).
Mice
Female DBA/2 mice (9 weeks old) were obtained from
Taconic (Germantown, NY) and were used throughout
the study.
Reagents
The following substances were used in this study: cipro-
floxacin (ICN Biomedicals, lot no.4913F), phosphorami-
don disodium salt, and 1,10-phenanthroline (Sigma,
MO), EDTA (GibcoBRL, CA), soybean trypsin inhibitor
from Glycine max (Sigma, MO), thermolysin (EC
3.4.24.27) from Bacillus thermoproteolyticus (Sigma, MO).
The fluorescently labeled casein and collagen type I for
determination of proteolytic acivity were from Molecular
Probes (OR). Zymogram gels were from Invitrogen
(Carlsbad, CA). Lethal factor (LF) and protective antigen
(PA) were from List Biological Laboratories (CA).
Preparation of secreted proteins
Secreted substances were prepared by culturing B. anthra-
cis  (delta Ames) in LB media overnight. Cells were
removed by centrifugation at 8000 g, and the supernatant
was sterilized by filtration through 0.22 µm cellulose ace-
tate filtration system (Corning, NY) and further concen-
trated 50-fold using Amicon Ultra15 centrifugal filter
devices (10 K cut-off pore size) (Millipore, MA). The pro-
teins were used immediately after preparation or were
stored at 4°C for several days. Protein content was deter-
mined using Bradford reagent (Bio-Rad) with bovine
serum albumin as standard. Slow reduction in the hemor-
rhagic activity was found upon storage within a week.
Fractionation of culture supernatants
1 ml of B. anthracis culture supernatant (BACS) was
loaded onto the size-exclusion Superdex column (25 × 60,
Pharmacia Biotech) and was eluted with PBS (pH 7.4)
with a flow rate of 2 ml/min. Fractions of eluate were con-
centrated to equal volumes using Centricon devices (Mil-
lipore, MA) with a 10 K cut-off pore size.
Hemorrhages in femoral artery region
Mice were anesthetized by intraperitoneal injection of
Avertin (2,2,2 tribromethanol, Aldrich) and 100 µl of
secreted proteins (20 to 100 µg) were subcutaneously
(s.c.) injected into the femoral artery region for observa-
tion of hemorrhagic changes after 3 to 15 h. In order toBMC Infectious Diseases 2005, 5:25 http://www.biomedcentral.com/1471-2334/5/25
Page 3 of 14
(page number not for citation purposes)
record hemorrhagic changes animals were anesthetized by
i.p. injection of Avertin and the fur over the femoral artery
region was removed to allow observation of a 1.5 to 2.5
cm2 area of skin. It was photographed, and the size of the
hemorrhagic spot was measured. In the experiments on
the inhibition of hemorrhagic effect the secreted proteins
were preincubated with specific antisera or protease
inhibitors for 30 min on ice.
Generation of antibodies against B. anthracis MPs
The Invitrogen (CA) custom service was used to obtain
rabbit polyclonal sera against peptides conjugated with
kallikrein (Table 1). Two animals were immunized by
each conjugate. All six rabbit sera had ELISA titers ranging
from 100,000 to 200,000. For generation of murine poly-
clonal antibodies against the M4 protease (BA3442) the
C-terminal part of the gene encoding amino acids 248 to
532 was cloned into pTrcHis2 TOPO TA cloning vector
(Invitrogen, CA). The recombinant protein containing a 6
× His tag was expressed in E. coli and purified using the Ni-
NTA resin (Quiagen, CA). Mice were immunized with 50
µg of the protein emulsified in a complete Freund's adju-
vant and were given two booster immunizations using an
incomplete adjuvant with 2 week intervals. Serum was
collected after two weeks since the last boost injection. In
the skin hemorrhagic test described above, 30 µl of serum
was able to completely suppress the hemorrhage caused
by 30 µl of BACS.
Intratracheal delivery of B. anthracis secreted proteins
Mice were anesthetized by i.p. injection of Avertin and a
24G angiogenic catheter (BD Biosciences, CA) was
inserted into the trachea. 50 µl of experimental mixture,
containing 10 to 100 µg of culture supernatant proteins
were slowly injected through the catheter connected to a
microsyringe. The angiogenic catheter was removed and
animals were left for further observation. The untreated
control group received the same volume of phosphate-
buffered saline (PBS). A control group of 3 animals was
injected with 50 µl of PBS solution of lethal toxin (100 µg
PA+100 µg LF). In all experiments the rate of breathing
was recorded every 10 min during the first 3 h following
injection, and animals were observed for survival for 7
days.
Detection of proteolytic activity of culture supernatants
Proteolitic activities of supernatants were measured using
EnzChek Protease assay kit (Molecular Probes) and
EnzChek Gelatinase/Collagenase assay kit (Molecular
Probes) according to the manufacturer's protocols.
Briefly, 5 µl of different dilutions of supernatant in 45 µl
of digestion buffer were mixed with 50 µl of fluorescein-
labeled substrate (casein or gelatin) and fluorescence
intensity was measured at different time points using 485
nm excitation and 530 nm emission wavelengths.
Treatment of spore-challenged mice
Mice used in all experiments were maintained under
proper conditions with a 12-h light/dark cycle in accord-
ance with IACUC standards in the animal facility of the
Biocon, Inc. (Rockville, MD). Mice received food and
water  ad libitum. Groups of 10 mice were randomly
assigned for challenge and were observed for survival and
signs of disease. The animals were inoculated i.p. by 1 ×
107 spores per mouse of Sterne strain. Treatment (i.p.)
with phenanthroline (30 mg/kg), phosphoramidon (10
mg/kg), or rabbit sera (5 or 25 mg/kg) was carried out
individually for each substance or in combination with
ciprofloxacin at (50 mg/kg) once a day started at different
time points post spore challenge and continued for 10
days. In all experiments the animals were monitored for
survival for at least 12 days after termination of treatment.
Statistical analysis
Kaplan-Meier open-end survival analysis was performed
to compare results between treatment groups. Statistical
significance was established as P < 0.05 using log-rank
test.
Table 1: Sera against B. anthracis proteases
Serum # Protease family Protein Gene number Antigen Designation
1 M4 Elastase-like neutral protease BA3442 Recombinant polypeptide corresponding to 
the fragment 248–532.
M4EL
2 M9 Collagenase BA0555, BA3299, 
BA3584
HEFTHYLQGRYEVPGL spanning the region 
of active center
M9Coll
3 M4 Neutral protease BA5282, BA0599 DVIGHELTHAVTE spanning the region of 
active center
M4AC
4 M4 Neutral protease BA2730 ADYTRGQGIETY distant from the active 
center
M4EPBMC Infectious Diseases 2005, 5:25 http://www.biomedcentral.com/1471-2334/5/25
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Results
Genomic analysis of B. anthracis secreted proteins as 
potential virulence factors
In order to evaluate a pathogenic potential attributed to
the  B. anthracis proteins other than known lethal and
edema toxins we used a nontoxigenic and nonencapsu-
lated strain of B. anthracis (delta Ames), which is a paren-
tal Ames strain cured of both plasmids, pXO1 and pXO2.
The substances secreted by vegetative B. anthracis cells
seem to be the most promising candidates, as is the case
for many bacterial toxins [10]. Analysis of the chromo-
some sequence of the B. anthracis Ames strain revealed a
variety of potential virulence-enhancing factors, including
collagenases, phospholipases, hemolysins, proteases and
other enterotoxins identified based on their sequence
homology with pathogenic factors in other bacterial spe-
cies [11]. The B. cereus group, which includes B. anthracis,
B. thuringiensis and B. cereus, has an expanded number of
predicted secreted proteins relative to nonpathogenic B.
subtilis [11]. These B. cereus group-specific genes represent
the ancestral adaptations to a pathogenic lifestyle by the
common ancestor, which was quite similar to B. cereus.
Our attention was attracted to the group of proteases that
are encoded on the B. anthracis chromosome, shared in
common with B. cereus but absent or relatively rare in the
genomes of nonpathogenic bacteria, such as B. subtilis and
B. halodurans. A large number of these proteases fall into
clan MA (classified according to the MEROPS system
[12]), which among others includes thermolysin-like
enzymes of the M4 family. Metalloproteases (MPs) from
several bacterial species belonging to this family are capa-
ble of causing massive internal hemorrhages and other
life-threatening pathologies [10,13-16].
Whole genome analyses also indicated collagenolytic pro-
teases of the M9B family as potentially having pathogenic
functions. Eleven protease families are present in B.
anthracis and B. cereus but absent in B. subtilis. Six of the
eleven subfamilies encode MPs. Three of the latter,
namely M6, M9B, and M20C subfamilies, are encoded on
the bacterial chromosomes. Members of the M6 peptidase
family are usually annotated as "immune inhibitors"
because in B. thuringiensis they can inhibit the insect anti-
bacterial response [17]. The M20C peptidase subfamily
represents exopeptidases [18] that are the unlikely cause
of tissue destruction or internal bleeding. Based on the
above analysis, this study focused on the M4 family ther-
molysin/elastase-like neutral proteases and the M9 family
collagenases as the candidate virulence-enhancing factors
of B. anthracis Aimes strain.
Hemorrhagic, caseinolytic and gelatinolytic activities of 
anthrax proteases
The proteins secreted by three Bacillus species (B. anthra-
cis, B. cereus and B. subtilis) into culture media were pre-
pared by successive steps of inoculation of the culture
media with spores, overnight incubation at 37°C,
removal of bacterial cells by centrifugation, sterilization of
the supernatant by filtration through 0.22 µ filter and fur-
ther 50-fold concentration using ultrafiltration devices
Amicon Ultra 15 (Millipore, MA) with a 10 KDa cutoff
size. The SDS-PAGE gel separation (Fig. 1A) demonstrates
the protein content in the concentrated B. anthracis cul-
ture supernatant (designated as BACS) used in our animal
tests. Similar procedures were used to prepare culture
supernatants for B. cereus ATCC #11778 and B. subtilis
ATCC #23857 (designated BCCS and BSCS, respectively).
Proteolytic activities of BACS are readily detected by
zymography using casein or gelatin (denatured collagen)
(Fig. 1D). A major band of gelatinase activity corresponds
to molecular mass of about 100 KDa, whereas a colla-
genase activity is represented by about 55 KDa proteins.
The concentrated culture supernatants were tested in
mice. Upon subcutaneous administration, mice devel-
oped hemorrhages of different intensity within several
hours (Fig. 2A, B). BCCS showed the highest activity fol-
lowed by BACS, while BSCS was completely inactive.
Chemical inhibitors such as phosphoramidon (potent
chelating inhibitor of thermolysin and other M4 bacterial
metallo-endopeptidases [19]), EDTA (specific for a broad
range of MPs) and soybean trypsin inhibitor (SBTI, revers-
ible competitive inhibitor of trypsin and other trypsin-like
proteases such as chymotrypsin, plasmin and plasma kal-
likrein [10]) effectively abrogated the hemorrhagic affect
of BACS (Fig. 2C). The murine serum raised against the
recombinant protein corresponding to the mature form of
the M4-type thermolysin-like neutral protease of B.
anthracis (gene identification number, BA 3442 according
to [11]) was also effective in suppressing the hemorrhagic
effect in the skin test. In negative control experiments, nei-
ther naïve murine serum nor three irrelevant murine sera
against B. anthracis candidate pathogenic factors, hemo-
lysins O, A and B [20] showed anti-hemorrhagic activity
(data not shown). Additional control experiments dem-
onstrated that under the conditions of our test the hemor-
rhagic activity of thermolysin from B. thermophilicus was
detectable in a dose range from 10 to 100 µg, similar to
that for BACS. In contrast to BACS, the inhibitors dis-
played only partial protection in the case of BCCS (Fig.
2C). Overall, these results correlate with the experimental
data that culture supernatants obtained from fully-viru-
lent toxigenic strain of B. anthracis were less toxic to mice
compared to B. cereus ones [9,21].
Generation of antibodies against B. anthracis MPs
Obvious complexity of the BACS protein composition
prompted us to develop specific means of detection and
inhibition of its components. For this purpose several
high-titer immune sera were raised in mice and rabbitsBMC Infectious Diseases 2005, 5:25 http://www.biomedcentral.com/1471-2334/5/25
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using the antigens listed in Table 1. The sera were used in
Western blots of BACS proteins. When the proteins were
directly separated in the SDS-PAGE for subsequent trans-
fer to the nitrocellulose membrane, the resulting blots
were of low intensity indicative of proteolytic degradation
during the electrophoresis (Fig. 1A and 1B, left lanes). In
order to avoid this complication the BACS was fraction-
ated according to the molecular masses of its components
on the Superdex size exclusion column in the presence of
EDTA as a chelating agent. Analysis of the column frac-
tions in SDS-PAGE showed a complex pattern of proteins
bands (Fig. 1). Multiple proteins with a broad spectrum of
molecular masses seem to be highly associated and
migrate through the column as high molecular mass com-
plexes. Several factors, such as the presence of multiple
precursor and mature protein forms resulting from spe-
cific proteolytic maturation, along with nonspecific prote-
olytic products, can potentially contribute to the
complexity of the fractions' composition. Western blot
experiments with column fractions revealed several dis-
crete bands recognized by antibodies (Fig. 1). The M4 pro-
teases are represented by several major bands at about 50
KDa, as well as by the bands at about 40 and 20 KDa.
These bands probably correspond to different maturation
forms of proteases, including the enzymes lacking signal
peptides, and mature enzyme forms. The M9 collagenases
are detected as a major band with a molecular mass of
about 98 kDa which is close to the estimated mass of the
pro-enzymes, however the major gelatinase enzymatic
activity corresponds to the 55 kDa proteins in the BACS.
Acute toxicity of B. anthracis culture supernatants
Although bacterial proteases are well known pathogenic
factors, little information is available regarding their acute
toxicity. We tested BACS in mice using intratracheal
administration into the lungs because hemorrhagic medi-
astinitis and lung edema typically precede the lethal out-
come in late anthrax. Therefore, lung damage may be
considered as a probable death-causing factor. Mice were
given different doses of BACS (10 µg to 40 µg of total pro-
tein) and were observed daily for lethality. Fig. 3 shows
that all mice challenged with different protein doses died
within 2 to 3 days, while the highest dose caused 80%
mortality on day 1. For histopathological examination
mice were given 100 µg of BACS protein. All animals died
within 3 to 4 hours. Postmortem harvested lungs revealed
focal intraalveolar acute hemorrhage, which was from
minimal to moderately severe with no endothelial cell
damage or vasculitis, and mild patchy congestion of
medium-size blood vessels. There was evidence of focal
platelet accumulation located within areas of hemorrhage
or within vessels. In a control experiment, lethal toxin at a
SDS-PAGE of BACS fractions separated on size exclusion column (A) and Western blots: fractions (A) with specific antisera a- M4EL (B), BACS with a-M4AC (C, left lane), BACS with a-M4EP (C, right lane), BACS with a-M9Coll (D, right lane), and zymo- grams of caseinolytic and gelatinolytic activities of BACS (D, left and center lanes, correspondingly) Figure 1
SDS-PAGE of BACS fractions separated on size exclusion column (A) and Western blots: fractions (A) with specific antisera a-
M4EL (B), BACS with a-M4AC (C, left lane), BACS with a-M4EP (C, right lane), BACS with a-M9Coll (D, right lane), and zymo-
grams of caseinolytic and gelatinolytic activities of BACS (D, left and center lanes, correspondingly). Molecular masses (KDa) of 
the marker proteins are indicated by arrows. In A, s denoted BACS, and numbers above correspond to column fractions. In 
zymogram gels 3 µl of BACS were loaded.
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comparable dose (100 µg LF, 100 µg PA) caused neither
mortality nor hemorrhage, and in fact, produced no sig-
nificant identifiable histopathological changes. In an
additional control experiment, 100 µg of BSCS protein
demonstrated no lethality (data not shown).
Protection of mice against anthrax using protease 
inhibitors
Effective suppression of the hemorrhagic activity of BACS
with chemical inhibitors prompted us to test their protec-
tive effect against B. anthracis infection. Two common
chemical inhibitors were tested in this study: phospho-
Hemorrhagic activity of culture supernatants (A), its graphic representation (B) and inhibition with chemical inhibitors (C) Figure 2
Hemorrhagic activity of culture supernatants (A), its graphic representation (B) and inhibition with chemical inhibitors (C). 100 
µl of secreted proteins (20 to 100 µg) were subcutaneously (sc) injected into the femoral artery region for observation of 
hemorrhagic changes. The fur over the femoral artery region was removed to allow observation of a 1.5 to 2.5 cm2 area of 
skin. Control mice were administered equal amount of phosphate-buffered saline. Error bars indicate standard deviations.
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ramidon and 1, 10-phenanthroline. As discussed above,
phosphoramidon inhibits the hemorrhagic effect of
BACS. It is a potent inhibitor of thermolysin and other
bacterial metallo-endopeptidases, but it does not inhibit
trypsin, papain, chymotrypsin or pepsin and weakly
inhibits collagenase [19]. Phenanthroline is a potent
chelating inhibitor of M4 MPs, such as pseudolysin, as
well as matrix MPs [10]. We first tested the above inhibi-
tors for their capacity against the bulk of gelatinase and
caseinase activity of BACS in vitro. It was found that up to
1 mM phosphoramidon did not inhibit the BACS gelati-
nase activity, while 50% of caseinolytic activity was inhib-
ited at the concentration of 0.1 mM (IC50). In contrast,
phenanthroline was more potent with gelatin as substrate
(IC50 0.01 mM), compared to casein (IC50 0.1 mM).
The B. anthracis delta Ames strain is avirulent in mice, and
therefore for the spore challenge experiments we used a
toxigenic Sterne strain. We have previously reported the
successful application of an adjunct therapy against
anthrax infection targeting both bacterial multiplication
and host response to infection by using a combination of
antibiotic and caspase inhibitors [22]. The same principle
was used in the current study because inhibition of
secreted pathogenic factors is not expected to directly
interfere with bacterial multiplication and therefore may
not be fully protective. In order to target both the bacteria
and the proteolytic factors we used a combination therapy
where antibiotic administration was complemented by
the administration of a protease inhibitor. We were also
interested in the efficacy of delayed treatment initiated
after certain periods of time following spore challenge. It
is a practically relevant scenario because patients generally
seek medical help after the onset of symptoms, and in
other patients treatment begins after a certain period of
time required to confirm the exposure. In addition, a
delayed ciprofloxacin therapy in murine model is only
partially protective when currently recommended human
antibiotic doses (adjusted for body weight) are used in
mice [22]. These conditions of treatment allowed us to
test if a combination approach could lead to a synergistic
enhancement in survival.
Results of three independent experiments are presented in
Figs. 4 and 5. Mice were challenged intraperitoneally (i.p.)
with about 1 × 107 of B. anthracis Sterne spores. Treatment
with a single daily dose of ciprofloxacin (50 mg/kg, i.p.)
began immediately after challenge, as well as at 24 h or 48
h post challenge, and continued for 10 days. In our condi-
tions the ciprofloxacin treatment initiated immediately
after spore challenge was only 70% effective in preventing
death. The survival rate after a 24 h delay in antibiotic
administration produced a sharp decline to 20% but
remained statistically reliable (compared to untreated
group, p = 0.015). After a 48 h delay the antibiotic was
completely ineffective (p = 0.23). The inhibitor treatment
without antibiotic was not able to improve survival, how-
ever the combination of ciprofloxacin with inhibitors dis-
played a synergistic increase in protection, especially
notable in the case of phenanthroline. The group receiv-
ing phenanthroline/ciprofloxacin treatment delayed by
24 h, demonstrated 70% protection of animals, compared
to only a 20% survival in the group with ciprofloxacin
alone (p = 0.03 for these groups). The 48 h-delayed regi-
men resulted in a statistically reliable 30% protection (rel-
ative to the untreated spore-challenged group, p < 0.05),
in contrast to ciprofloxacin alone (relative to the
untreated spore-challenged group, p = 0.23). There is a
similar trend in the efficacy of the combination phospo-
ramidon/ciprifloxacin therapy, compared to ciprofloxacin
alone, however the observed differences are less reliable
(p > 0.05).
Protection of mice against B. anthracis using anti-
protease sera
As in the experiments with inhibitors, mice were chal-
lenged intraperitoneally (i.p.) with about 30 LD50 of B.
anthracis Sterne spores. Treatment with a single daily dose
of ciprofloxacin (50 mg/kg, i.p.) began at 24 h post chal-
lenge and continued for 10 days. The immune sera (each
pulled from two rabbits) were administered once daily at
Survival of mice upon intratracheal injection of BACS Figure 3
Survival of mice upon intratracheal injection of BACS.
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Protection of mice against B. anthracis (Sterne) infection by administration of ciprofloxacin and its combination with phospho- ramidon for 10 days beginning 24 h and 48 h post spore challenge Figure 4
Protection of mice against B. anthracis (Sterne) infection by administration of ciprofloxacin and its combination with phospho-
ramidon for 10 days beginning 24 h and 48 h post spore challenge.
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Protection of mice against B. anthracis (Sterne) infection by administration of ciprofloxacin or its combination with phenanthro- line for 10 days beginning 24 h and 48 h post spore challenge Figure 5
Protection of mice against B. anthracis (Sterne) infection by administration of ciprofloxacin or its combination with phenanthro-
line for 10 days beginning 24 h and 48 h post spore challenge.
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a concentration of 25 mg/ml (i.p.). The sera displayed
substantial differences in their protective effect (Fig. 6).
The anti-M4 serum against the epitope(s) of the active
center displayed the highest protection (60%; p = 0.038
compared to naïve serum). The rest of the immune sera,
namely the anti-collagenase serum anti-M9Coll and the
anti-neutral protease serum anti-M4EP behaved similar to
the naïve serum. All three latter sera demonstrated a bor-
derline protection from 10% to 30%, compared to
untreated mice (p = 0.028, 0.084, and 0.052, respec-
tively), however the difference in survival between them
was statistically unreliable (p > 0.41).
A combination treatment with both antibiotic and all
studied immune sera, administered at the dose of 25 mg/
kg was strongly synergistic and protected from 80 to 100%
mice with high statistical significance (p = 0.0024, 0.0058,
and 0.016 for anti-M9, anti-M4EP, and anti-M4AC, corre-
spondingly, compared to the effect of naïve serum-antibi-
otic combination). A lower serum dose (5 mg/kg) showed
a similar pattern of protection, however the effect of com-
bination treatment was reduced to 70%. Some synergistic
protection was also noticed in the case of naïve serum
(perhaps due to its natural bactericidal properties),
although it is statistically unreliable compared to antibi-
otic-alone group.
Discussion
In order to be highly virulent, any pathogenic microbe is
required to possess the means to effectively establish and
further propagate the infectious process. Distinct
virulence factors may be necessary to fulfill these require-
ments at different stages of the disease. B. anthracis is a
recently emerged highly virulent pathogen, which
acquired two plasmids pXO1 and pXO2 compared to the
genetically similar but opportunistic pathogen B. cereus.
These plasmids encode for the lethal toxin (LT) and cap-
sule genes, respectively [4]. LT is a secreted protein, which
has long been considered as a major late virulence factor.
It appears in the circulation at the septisemic stage of the
disease shortly before death [23,24]. LT is the only
anthrax protein, which was found toxic in experimental
animals [23,24], and this discovery essentially abrogated
further research efforts on other potential virulence fac-
tors. However, it has long been known that systemic tox-
icity of LT is low [24,25], and that the histopathology of
LT intoxication differs considerably from that found in
clinical anthrax infection [5,6]. It is especially notable that
postmortem examination of victims from the Sverdlovsk
accident and those autopsied following the 2001 U.S.
anthrax attacks [2,4] revealed hemorrhagic thoracic lym-
phadenitis and necrotizing hemorrhagic mediastinitis in
all patients. About half of the Sverdlovsk victims addition-
ally had hemorrhagic meningitis [2]. These severe life-crit-
ical symptoms had not been noticed in the intoxicated
animals.
Recent data, however, suggest a new important role of LT
as a disease-establishing virulence factor playing an
immunosuppressive role within alveolar macrophages at
the early stages of inhalation anthrax [for review, see ref.
[26]]. The immunosuppressive capacity of LT is limited,
and therefore LT may not completely inhibit the pro-
inflammatory host response [27]. Nevertheless, the LT
activity does help anthrax spores to survive in the hostile
environment, which contributes to the decrease in the
infectious dose. It has been demonstrated that LT caused
apoptotic death of macrophages and that its inhibition
decreased survival of B. anthracis spores engulfed by mac-
rophages [28]. These data suggested that the major roles
of LT and ET might actually be to provide a more hospita-
ble environment for the pathogen intra-phagocytic sur-
vival. This hypothesis helps explain the low virulence of
the plasmid-free strains of both B. anthracis and B. cereus
upon spore challenge [29] in spite of the highly toxic pro-
teolytic capacity of these species.
While only fragmented data have been reported on the
existence of B. anthracis chromosome-encoded virulence
factors [20,30,31], it is well established that B. cereus pro-
duces a variety of pathogenic determinants, including a
necrotizing enterotoxin, an emetic toxin, extracellular
proteases, phospholipases and hemolysins [32]. B. cereus
is capable of causing serious and sometimes lethal infec-
tions such as sepsis, pneumonia, meningitis, endocarditis,
wound and ocular infections, especially in immunocom-
promised individuals [32-35]. A highly virulent isolate of
B. cereus has recently been identified which contains a
plasmid 99.6% similar to pXO1 [36]. This finding is con-
sistent with the point of view that the B. cereus genetic
background is sufficient for high virulence when it is com-
plemented with an infection-establishing virulence factor
such as LT. Complete sequencing of the B. anthracis and B.
cereus  genomes confirmed their close relationship sug-
gested previously [37] and allowed us to suggest new can-
didate virulence factors for B. anthracis, specifically the
proteases of the M4 and M9 families. Structurally similar
proteolytic factors in other pathogenic microorganisms
are known to be involved in inactivation of complement
factors [38], cleavage of serum protease inhibitors [39],
activation of blood coagulation system [40], invasiveness
into the host tissue [41], and development of hemor-
rhages [13].
We demonstrate here that secreted metalloproteases
(MPs) of B. anthracis can digest protein substrates such as
casein and gelatin in vitro, and can induce a hemorrhagic
process in our test subjects, in vivo. Both of these activities
are inhibited by chemical inhibitors of M4 and M9 MPs,BMC Infectious Diseases 2005, 5:25 http://www.biomedcentral.com/1471-2334/5/25
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Post exposure efficacy of hyperimmune rabbit sera in mice challenged with B. anthracis (Sterne) Figure 6
Post exposure efficacy of hyperimmune rabbit sera in mice challenged with B. anthracis (Sterne). Treatment with sera and cip-
rofloxacin was initiated 24 h post exposure and continued for 10 days once daily.
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such as EDTA, phosphoramidon and 1, 10-phenanthro-
line. Consistent with this, the hyper-immune mouse
serum against M4 family thermolysin/elastase-like
enzyme is capable of inhibiting the hemorrhagic effect of
BACS (we currently investigate the in vitro inhibiting activ-
ity of the hyper-immune sera used in this report). The tis-
sue-damaging action of this type of enzymes is well
known [10]. For example, pseudolysin, an elastase of
Pseudomonas aeruginosa, destroys arterial elastic laminae in
systemic infection, causes lung damage with hemorrhages
and necrosis, and induces septic shock through activation
of the host kinin cascade [42-44].
In the present study we used an intratracheal (i.t.) admin-
istration to demonstrate that tissue destructive and hem-
orrhagic properties of BACS could cause a lethal effect at
0.5 to 3 mg/kg doses of total protein (10 to 60 µg per 20
g DBA/2 mouse) within a few days or even hours (Fig. 3).
Histopathological examination confirmed our observa-
tions of life-threatening severe bleeding upon administra-
tion of BACS. It has been reported that P. aeruginosa
elastase induced an immediate lethal shock in guinea pigs
upon an i.v. injection at a similar dose of 1.2 mg/kg [44].
Compared to BACS, the LT is non-toxic upon an i.t.
administration. There is no mortality in a control group of
LT-treated mice (200 µg/mouse, i.t.). Recently, the toxicity
of highly purified LT was re-evaluated in BALB/CJ and
C57BL/6J mice, and it was found that doses from 5 to 12.5
mg/kg (i.v.) were required for up to 90% mortality in 5
days [6]. We conclude that secreted proteins of B. anthra-
cis, in addition to LT and ET, have high pathogenic poten-
tial and should be considered as important virulence
factors.
We have previously suggested a combination antibiotic-
antitoxin approach to anthrax therapy and for the first
time demonstrated an increased efficacy of ciprofloxacin
treatment in a murine model when it was combined with
a caspase inhibitor administration [22]. Up to now, there
has been no other report on any anti-LT treatment during
the anthrax infectious process. In the present study, we
used two new combination therapies, namely the antibi-
otic-protease inhibitor and the antibiotic-antiserum ones.
Both of them also proved beneficial, compared to antibi-
otic alone. It is especially important to note that we used
the delayed treatment regiments, which are inherently less
effective, compared to prophylactic drug administration.
Currently, a considerable effort is directed towards devel-
opment of specific LT inhibitors (see for example [45-47])
while their efficacy in the treatment of the infectious proc-
ess has not been reported. In contrast, the inhibitors we
used (phosphoramidon and phenanthroline) to model
anthrax therapy are not considered as LT inhibitors [47],
however in our experiments both of these substances
increased survival during ciprofloxacin therapy, which
was initiated at 24 h and 48 h post challenge. The phen-
anthroline-ciprofloxacin combination administered 24 h
post challenge protected 70% of the mice, compared to
20% for antibiotic alone. Late stages of anthrax are espe-
cially difficult to treat [4]. In our model the 48 h post chal-
lenge time approximately correlates with the period of
typical overt anthrax symptoms in patients because 30%
of mice die within the next 24 h, a situation that is similar
to that clinically observed in natural human infection. In
these circumstances, our therapy with phenanthroline-
ciprofloxacin was 30% protective, while ciprofloxacin
alone was ineffective. It is worth pointing out that the
high extent of protection (70% after 24 h delay) conferred
by a combination of antibiotic with phenanthroline
argues in favor of the substantial role of secreted proteases
as death-causing factors, although their contribution to
mortality relative to LT is currently unknown. We have
previously reported that in similar experimental condi-
tions the caspase inhibitor YVAD, capable of protecting
macrophages against LT-induced apoptosis, improved
survival of DBA/2 mice by 30%. One may therefore expect
that a triple component therapy, such as ciprofloxacin-
phosphoramidon-caspase inhibitor, might be completely
protective. Experiments in this direction are in progress. In
connection with the question on the role of LT, we also
currently investigate a spectrum of neutralizing activity of
immune sera used in this study.
Conclusion
Overall, our data demonstrate that B. anthracis cultivated
in culture media secrets a number of proteolytic virulence
factors, including those with hemorrhagic, caseinolytic
and gelatinolytic activities. These factors in most respects
are distinct from LT, including the mode of their expres-
sion under aerobic conditions (LT requires bicarbonate
for its expression in vitro [48]), their molecular targets, as
well as a high virulent potency upon intratracheal admin-
istration. Chemical inhibitors of these factors as well as
immune sera raised against them in rabbits demonstrate a
substantial protective efficacy in combination with antibi-
otic therapy. Our findings outline a new direction in the
development of anthrax therapeutic approaches, and
close a substantial gap between the understanding of
anthrax molecular pathology and the most prominent
clinical features of its infectious process. Complexity of
the BACS composition with regard to the number and
specificity of proteolytic enzymes suggests a multitude of
their potential virulent mechanisms that need to be
explored further.
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